Pharming Group N.V. — Form 6-K Summary
Reporting date: April 22, 2021. The filing reports a press release concerning clinical development; it does not provide quarterly or annual financial results.
Business Context and Reporting Period
Pharming is a commercial-stage biopharmaceutical company focused on protein replacement therapies and precision medicines for rare diseases and other unmet medical needs. Its lead product, RUCONEST® (recombinant human C1 esterase inhibitor), is approved for treating acute hereditary angioedema attacks and is commercialized in the United States, European Union and United Kingdom through Pharming’s own organization.
The company announced enrollment of the first patient in a multicenter, double-blind, randomized, controlled Phase IIb trial evaluating RUCONEST for prevention of acute kidney injury following percutaneous coronary intervention in patients with non-ST elevation myocardial infarction. The first patient was enrolled at University Hospital Basel, Switzerland, with additional Swiss centers expected to participate.
Key Financial and Operating Metrics
- The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, working-capital, or other financial metrics.
- The Phase IIb study is planned to include up to 220 patients.
- The primary endpoint is the peak increase in urinary NGAL within 24 hours after treatment, comparing rhC1INH with placebo.
- Additional endpoints include acute kidney injury based on serum creatinine within 72 hours, cardiovascular and renal events, and hospitalization-related medical resource utilization over six months.
Material Changes Versus the Prior Comparable Period
No period-over-period financial comparison is provided. The material development disclosed is the initiation of patient enrollment in the Phase IIb study, following encouraging results from a 2018 investigator-initiated Phase II trial.
In the relevant Phase II subgroup undergoing percutaneous coronary intervention, the median percentage change in peak urinary NGAL within 48 hours was 11.3% for RUCONEST-treated patients versus 205.2% for placebo, with a reported p-value of 0.001. These earlier results are not Phase IIb results and do not establish efficacy in the new study.
Guidance, Outlook, Risks and Unusual Items
- Management stated that the new study could clarify RUCONEST’s role in preventing acute kidney injury after myocardial infarction and, if successful, support development for additional causes of acute kidney injury.
- Pharming is also investigating rhC1INH for pre-eclampsia, acute kidney injury and severe pneumonia associated with COVID-19, and is developing leniolisib for activated PI3K delta syndrome.
- The filing provides no specific revenue, earnings, cash, or clinical-development guidance.
- Forward-looking statements are subject to risks involving clinical-trial scope, enrollment, timing, costs, scientific and technical developments, regulatory approval, commercial prospects, and the effects of the COVID-19 pandemic.
- Study enrollment and favorable prior biomarker results do not guarantee clinical efficacy, regulatory approval, commercialization, or financial returns.
- The release states that the disclosure qualified, or may have qualified, as inside information under the EU Market Abuse Regulation.
Important Facts for Investors to Verify
- Progress of enrollment and completion of the planned Phase IIb trial across Swiss centers.
- Whether the primary urinary NGAL endpoint and secondary clinical endpoints demonstrate statistically and clinically meaningful benefit.
- The appropriate dosing regimen and the potential design, scope and cost of any subsequent trials.
- Regulatory feedback and the feasibility of expanding RUCONEST into acute kidney injury and other investigational indications.
- Financial position, liquidity, cash resources and clinical-development spending, which are not disclosed in this filing and should be reviewed in Pharming’s 2020 Annual Report and Form 20-F.